| CAS NO: | 854107-55-4 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 25mg | 电议 |
| Cas No. | 854107-55-4 |
| 别名 | ACT-128800 |
| 化学名 | (2E,5Z)-5-(3-chloro-4-((S)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one |
| Canonical SMILES | O=C1N(C2=CC=CC=C2C)/C(S/C1=C\C3=CC=C(OC[C@@H](O)CO)C(Cl)=C3)=N\CCC |
| 分子式 | C23H25ClN2O4S |
| 分子量 | 460.97 |
| 溶解度 | DMF: 5 mg/ml,DMSO: 5 mg/ml,DMSO:PBS(pH 7.2) (1:3): 0.25 mg/ml |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | EC50: 5.7 nM Ponesimod is a sphingosine-1-phosphate receptor 1 (S1P1) modulator. Lymphocyte exit from lymph nodes and its recirculation into blood is reported to be controlled by S1P. The cellular receptor mediating lymphocyte exit is one of five S1P receptors, S1P1. Thus, the nonselective agonists for S1P1 lead to blood lymphocyte count reduction. In vitro: Previous study found that ponesimod could activate S1P1-mediated signal transduction with high potency. Moreover, relative to the potency for S1P, the potency of ponesimod at human recombinant receptors was 4.4-fold higher for S1P1 and 150-fold lower for human S1P3. Thus, ponesimod was 650-fold more selective for human S1P1 over S1P3 than the endogeneous ligand [1]. In vivo: Animal study showed that the oral administration of ponesimod to rats resulted in a dose-dependent decrease of blood lymphocyte count, and the blood lymphocyte count returned to baseline within 48 h after discontinuation of ponesimod treatment. In addition, ponesimod prevented inflammatory cell accumulation, edema formation, as well as cytokine release in the skin of mice with delayed-type hypersensitivity. Furthermore, in rats with adjuvant-induced arthritis, ponesimod could also prevent the increase in paw volume and joint inflammation [2]. Clinical trial: Clinical data have shown a dose-dependent therapeutic effect of ponesimod, acceptable safety and tolerability. Furthermore, phase II clinical data have also shown therapeutic efficacy of ponesimod in psoriasis [2]. References: |
m.cnreagent.com